Welcome to our dedicated page for Camp4 Therapeutics SEC filings (Ticker: CAMP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The CAMP4 Therapeutics Corporation (Nasdaq: CAMP) SEC filings page on Stock Titan provides access to the company’s U.S. Securities and Exchange Commission disclosures, including current reports on Form 8-K and other registered offerings. CAMP4 identifies itself in these filings as a clinical-stage biopharmaceutical company developing regulatory RNA-targeting therapeutics and antisense oligonucleotide (ASO) drug candidates to upregulate gene expression for genetic diseases.
Through its Form 8-K filings, CAMP4 reports material events such as securities purchase agreements, private placements, and underwritten offerings of common stock registered on Form S-3. These filings describe how the company expects to use proceeds to support preclinical and clinical development of product candidates, including its SYNGAP1 program, and to fund working capital and general corporate purposes.
CAMP4’s 8-K filings also detail strategic collaboration agreements, including a research, collaboration and license agreement with GSK covering antisense oligonucleotide therapeutics targeting regulatory RNAs for neurodegenerative and kidney disease indications. The filings outline key terms such as exclusive worldwide licenses under certain patents and know-how, upfront payments, potential development and commercial milestones, and tiered royalties on net sales.
Additional 8-Ks address corporate governance and compensation matters, including changes to the board of directors, inducement equity grants under Nasdaq Listing Rule 5635(c)(4), and registration rights agreements associated with private placements. As an emerging growth company, CAMP4 uses these reports to communicate significant operational, financing, and collaboration developments.
On Stock Titan, investors can review CAMP4’s filings alongside AI-powered summaries that explain the significance of each document. Users can quickly see highlights from annual and quarterly reports when available, track current reports on Form 8-K, and monitor equity financing terms, collaboration structures, and other regulatory disclosures relevant to CAMP4’s RNA-targeting therapeutic pipeline.
CAMP4 Therapeutics Corporation furnished an update on its business by providing investors with its financial results for the quarter ended September 30, 2025. The company reported these quarterly results through a press release dated November 6, 2025, which is attached as Exhibit 99.1.
The 8-K clarifies that the press release and related information are considered “furnished” rather than “filed” under securities laws, which limits certain legal liabilities and controls how the information may be incorporated into other regulatory documents.
CAMP4 Therapeutics filed a resale registration covering 33,431,131 shares of Common Stock and 6,003,758 shares issuable upon exercise of its 2025 pre-funded warrants. The filing registers shares issued in a September 2025 private placement and 6,713,717 piggyback shares under an existing investors’ rights agreement.
The company is not offering any shares and will not receive proceeds from selling stockholder resales, other than any cash received upon warrant exercises. The 2025 pre-funded warrants carry a $0.0001 per-share exercise price and include beneficial ownership limits of 4.99% or 9.99% (adjustable to up to 19.99% with notice). As context, shares outstanding were 46,880,185 as of October 1, 2025. The company notes the registered resale shares represent approximately 69% of outstanding shares as of that date, which could pressure the stock if sold.
Initial Form 3 filing shows Dr. Daniel Tardiff, Chief Scientific Officer and director at Camp4 Therapeutics (CAMP), reporting ownership entirely through stock options. He holds options covering 74,578 shares of common stock with exercise prices of $9.08, $3.86, and $3.53. Vesting schedules start on 09/18/2023 and 04/01/2025
FMR LLC and Abigail P. Johnson reported owning a combined 3,023,434 shares of Camp4 Therapeutics Corp common stock, representing 15.0% of the outstanding class as of 09/30/2025. FMR LLC identifies itself as the filing person and notes that Select Biotechnology Portfolio held 1,463,592 shares, or 7.3%, of the company at that date. The filing states the shares were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control. Signatures show the form was executed on 10/06/2025 by an authorized representative.
Camp4 Therapeutics Schedule 13G/A: HarbourVest-affiliated entities report beneficial ownership of 1,271,948 shares of Camp4 common stock, representing 2.7% of the class. The shares are owned directly by SMRS-TOPE LLC, which holds sole voting and dispositive power over all 1,271,948 shares. HarbourVest Partners, LLC, HarbourVest Partners L.P. and HVST-TOPE LLC may be deemed to have shared voting and dispositive power but disclaim beneficial ownership. The filing includes a joint filing agreement among the reporting persons and is based on 46,842,126 shares outstanding used to calculate the 2.7% stake.
CAMP4 Therapeutics Corporation furnished an update that it has initiated GLP (good laboratory practice) toxicology studies for its program called CMP-SYNGAP-01. These studies are a standard non‑clinical step used to evaluate safety before a potential move into later development stages.
The update was shared through a press release titled “CAMP4 Therapeutics Initiates GLP Toxicology Studies for CMP-SYNGAP-01,” which is included as an exhibit to this report. The information is being provided for disclosure purposes and is not being treated as filed under the securities laws unless specifically incorporated by reference elsewhere.
Vivo Opportunity funds disclosed ownership positions in Camp4 Therapeutics (CAMP). Together, Vivo Opportunity Fund Holdings, L.P. and its general partner Vivo Opportunity, LLC report beneficial ownership of 3,561,793 shares, representing 7.6% of the class based on a 46,878,487-share base that includes a 26,717,414-share private placement closed September 11, 2025. Separate Cayman entities, Vivo Opportunity Cayman Fund, L.P. and its GP, report beneficial ownership of 359,775 shares (0.8%). All reported shares are held of record by the named funds, and the filers state sole voting and dispositive power over the shares. The filing is a Schedule 13G indicating passive investment intent.
Vivo Opportunity funds disclosed ownership positions in Camp4 Therapeutics (CAMP). Together, Vivo Opportunity Fund Holdings, L.P. and its general partner Vivo Opportunity, LLC report beneficial ownership of 3,561,793 shares, representing 7.6% of the class based on a 46,878,487-share base that includes a 26,717,414-share private placement closed September 11, 2025. Separate Cayman entities, Vivo Opportunity Cayman Fund, L.P. and its GP, report beneficial ownership of 359,775 shares (0.8%). All reported shares are held of record by the named funds, and the filers state sole voting and dispositive power over the shares. The filing is a Schedule 13G indicating passive investment intent.
Coastlands-affiliated entities and Matthew D. Perry reported holding an aggregate of 4,886,722 shares of Camp4 Therapeutics Corp common stock. The filing lists that amount as representing 10.0% of the class on the cover sheets and as 9.99% in Item 4, reflecting the reporting persons' calculation based on 20,161,073 shares outstanding as of August 5, 2025 and an additional 26,681,053 shares issued in a private placement that closed September 11, 2025. Each reporting person disclaims beneficial ownership except to the extent of pecuniary interest and states the shares are held in the ordinary course of business and not to influence control of the issuer. All reporting persons show shared voting and dispositive power over the 4,886,722 shares and no sole voting or dispositive power.
Andrew J. Schwab, a director and 10% owner of Camp4 Therapeutics Corp (CAMP), reported an acquisition on Form 4. The filing shows a transaction dated 09/11/2025 in which 2,941,176 shares of common stock were acquired at $1.53 per share. The shares are reported as indirectly owned through 5AM Ventures VII, L.P. The filing also discloses additional indirect holdings attributed to related 5AM entities: 2,625,145 shares held by 5AM Ventures VI, L.P. and 302,770 shares held by 5AM Opportunities II, L.P. Explanatory footnotes state Schwab is a managing member of the general partner entities and disclaims direct beneficial ownership except to the extent of pecuniary interest.
Camp4 Therapeutics insider acquisition: Multiple 5AM-affiliated entities and Kush Parmar reported purchases and beneficial holdings of Camp4 Therapeutics (CAMP) common stock. On 09/11/2025 a purchase transaction (code P) was reported for 2,941,176 shares at $1.53 per share. The filing lists beneficial holdings following the transaction: 2,941,176 shares held by 5AM Ventures VII, L.P., 2,625,145 shares by 5AM Ventures VI, L.P., and 302,770 shares by 5AM Opportunities II, L.P. The reporting parties disclose indirect ownership through related general partner entities and state shared voting and investment power; the statements include disclaimers limiting beneficial ownership to pecuniary interest.